Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 207968

Expand all

JADENU SPRINKLE (DEFERASIROX)
90MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: JADENU SPRINKLE
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 90MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N207968
Product Number: 001
Approval Date: May 18, 2017
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

JADENU SPRINKLE (DEFERASIROX)
180MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: JADENU SPRINKLE
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 180MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: 
Application Number: N207968
Product Number: 002
Approval Date: May 18, 2017
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

JADENU SPRINKLE (DEFERASIROX)
360MG Marketing Status: Prescription

Active Ingredient: DEFERASIROX
Proprietary Name: JADENU SPRINKLE
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 360MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N207968
Product Number: 003
Approval Date: May 18, 2017
Applicant Holder Full Name: NOVARTIS PHARMACEUTICALS CORP
Marketing Status:  Prescription
Patent and Exclusivity Information

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English